Humulin N (Nph) Kwikpen (Insulin Human (Rdna))

Humulin N Kwikpen is prescribed for patients who need long‑acting insulin support to control blood glucose levels. It is commonly used in the following clinical situations:

• Basal insulin therapy for type 1 diabetes mellitus.
• Basal insulin therapy for type 2 diabetes mellitus.
• Combination with rapid‑acting insulin analogues for a basal‑bolus regimen.
• Management of fasting glucose and overnight glycaemic control.
• Adjustments during periods of increased insulin resistance, such as illness or steroid therapy.

• Insulin human (NPH) in Humulin N Kwikpen binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor’s intrinsic tyrosine kinase activity. This triggers downstream signaling pathways that promote glucose transporter (GLUT4) translocation, enhancing cellular glucose uptake, and suppresses hepatic gluconeogenesis. The protamine complex slows absorption, extending the duration of action to provide intermediate‑acting basal insulin coverage.

Adverse reactions to Humulin N Kwikpen vary in frequency and severity.

Common

• Hypoglycaemia (low blood glucose)
• Injection site redness, swelling or itching
• Lipodystrophy (localized fat loss or accumulation)
• Weight gain
• Mild nausea

Serious

• Severe hypoglycaemia requiring assistance
• Allergic reactions such as urticaria or angioedema
• Anaphylaxis (rare)
• Persistent hyperglycaemia indicating insulin resistance or dosing error

When using Humulin N Kwikpen, several safety considerations should be observed:

• Monitor blood glucose regularly to detect hypoglycaemia early.
• Adjust dose during periods of illness, pregnancy, or when starting/stopping other glucose‑lowering agents.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Educate patients on proper injection technique to minimise lipodystrophy.
• Avoid use in individuals with known hypersensitivity to human insulin or protamine.
• Review any history of cardiovascular disease, as rapid glucose fluctuations can affect cardiac risk.

Humulin N Kwikpen may interact with other medications, influencing its glucose‑lowering effect.

Avoid

• Concurrent use of other insulin products without dose adjustment, which can cause severe hypoglycaemia.
• High‑dose beta‑blockers that may mask hypoglycaemia symptoms.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycaemia risk.
• Corticosteroids, which can raise blood glucose and require dose escalation.
• Thiazide diuretics and ACE inhibitors, which may affect potassium balance and insulin sensitivity.
• Alcohol, as it can cause unpredictable glucose changes.
• Certain antidepressants (e.g., MAO inhibitors) that may alter glucose metabolism.